| Joseph J Catalina, CRNA | |
|
5301 S Congress Ave, Atlantis, FL 33462-1149 | |
| (561) 965-7300 | |
| Not Available |
| Full Name | Joseph J Catalina |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 17 Years |
| Location | 5301 S Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003074303 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP3164422 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Atlantis, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Physician Solutions Of South Florida, Llc | 4688805286 | 220 |
| Galloway Anesthesia Associates Llc | 0143402917 | 78 |
News Archive
Pro-market policies for developing countries have long been based on the belief that increasing average income is key to improving public health and societal well-being.
Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
› Verified 6 days ago
| Entity Name | Sheridan Healthcorp Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629781711 PECOS PAC ID: 3173429693 Enrollment ID: O20031208000355 |
News Archive
Pro-market policies for developing countries have long been based on the belief that increasing average income is key to improving public health and societal well-being.
Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
› Verified 6 days ago
| Entity Name | Galloway Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689989139 PECOS PAC ID: 0143402917 Enrollment ID: O20110315001054 |
News Archive
Pro-market policies for developing countries have long been based on the belief that increasing average income is key to improving public health and societal well-being.
Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
› Verified 6 days ago
| Entity Name | Ocala Anesthesia Ams Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699197343 PECOS PAC ID: 4789814617 Enrollment ID: O20140220000864 |
News Archive
Pro-market policies for developing countries have long been based on the belief that increasing average income is key to improving public health and societal well-being.
Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
› Verified 6 days ago
| Entity Name | Anesthesia Physician Solutions Of South Florida, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104248699 PECOS PAC ID: 4688805286 Enrollment ID: O20140325000665 |
News Archive
Pro-market policies for developing countries have long been based on the belief that increasing average income is key to improving public health and societal well-being.
Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph J Catalina, CRNA 1613 Harrison Pkwy, Bldg C, Suite 200, Sunrise, FL 33323-2896 Ph: (954) 838-2502 | Joseph J Catalina, CRNA 5301 S Congress Ave, Atlantis, FL 33462-1149 Ph: (561) 965-7300 |
News Archive
Pro-market policies for developing countries have long been based on the belief that increasing average income is key to improving public health and societal well-being.
Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
› Verified 6 days ago
Heather N Stokes, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Danielle Witkowski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 Fax: 954-514-3979 | |
Lidiya Pastukh, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Eileen O'hara, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Jennifer Vanetti Quinn, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Jfk Medical Center, Atlantis, FL 33462 Phone: 561-965-7300 | |
Priscilla Dias, RN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S. Congress Ave, Jfk Medical Center,, Atlantis, FL 33462 Phone: 561-548-9275 |